-
-
-
-
-
-
-
AstraZeneca acquires Modella AI to expand oncology AI capabilities
-
-
-
-
-
-
-
AstraZeneca's 9M and Q3 2025 Financial Results
-
-
-
-
-
-
-
AstraZeneca results: H1 and Q2 2025
-
-
-
-
-
-
-
AstraZeneca (AZN) to acquire EsoBiotec
-
-
-
-
-
-
-
AstraZeneca (AZN) Tops Q2 EPS by 99c; offers guidance
-
-
-
-
-
-
-
VOYDEYAâ„¢ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
-
-
-
-
-
-
-
AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development
-
1,159,566 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

